Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2027529 | Steroids | 2016 | 9 Pages |
•Modification on bile acids resulted in the identification of FXR/GPBAR1 modulators.•All derivatives were evaluated on FXR and GPBAR1 transactivation.•Cholanoic acids are the first example of GPBAR1 antagonists.•Cholanoic acids are novel chemical probes in FXR mediated liver disorders.
Bile acids, the end products of cholesterol metabolism, activate multiple mechanisms through the interaction with membrane G-protein coupled receptors including the bile acid receptor GPBAR1 and nuclear receptors such as the bile acid sensor, farnesoid X receptor (FXR). Even if dual FXR/GPBAR1 agonists are largely considered a novel opportunity in the treatment of several liver and metabolic diseases, selective targeting of one of these receptors represents an attractive therapeutic approach for a wide range of disorders in which dual modulation is associated to severe side effects. In the present study we have investigated around the structure of LCA generating a small library of cholane derivatives, endowed with dual FXR agonism/GPBAR1 antagonism. To the best of our knowledge, this is the first report of bile acid derivatives able to antagonize GPBAR1.